What the latest volume-based procurement changes in China mean for pharma
td { padding: 10px; font-family: var(--font-family-sk); } td img { width: 50px; }
The latest round of VoBP signals more transparency and balanced considerations, with more opportunities for the industry to strategize and plan ahead.
The 11th round of China’s national volume-based procurement (VoBP) was announced in July 2025, covering 55 drugs across 14 therapeutic areas.
As widely anticipated, many of the drugs on the list are blockbusters like Cefzil, Forxiga, Lynparza, and Evrenzo. These drugs carry sizable budget implications and face extensive generic competition – both key triggers for VoBP inclusion.
Source: Simon-Kucher, NHSA, Insight database. VoBP: Volume-based procurement; TA: Therapeutic area.
Goodwill signals
Unlike the last 10 rounds of national VoBPs, there were several goodwill signals that came with the latest announcement. These were partly a response to backlash from earlier tenders and shaped by…
